A detailed history of Polaris Capital Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Polaris Capital Management, LLC holds 61,900 shares of EXEL stock, worth $2.2 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
61,900
Previous 61,900 -0.0%
Holding current value
$2.2 Million
Previous $1.39 Million 15.54%
% of portfolio
0.09%
Previous 0.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 07, 2024

SELL
$19.25 - $24.13 $346,500 - $434,340
-18,000 Reduced 22.53%
61,900 $1.48 Million
Q4 2022

Feb 09, 2023

BUY
$14.96 - $17.39 $552,024 - $641,691
36,900 Added 85.81%
79,900 $1.28 Million
Q2 2022

Aug 12, 2022

SELL
$17.44 - $23.16 $2.74 Million - $3.64 Million
-157,000 Reduced 78.5%
43,000 $895,000
Q2 2022

Aug 10, 2022

BUY
$17.44 - $23.16 $3.49 Million - $4.63 Million
200,000 New
200,000 $4.31 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Polaris Capital Management, LLC Portfolio

Follow Polaris Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polaris Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Polaris Capital Management, LLC with notifications on news.